Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

NCT04204941 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT04204941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04204941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Lead sponsor
Epizyme, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 19, 2019
Completion date
June 14, 2024
Enrollment
25 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced epithelioid sarcoma, advanced soft-tissue sarcoma